Could Cerus Corporation (CERS) See a Reversal After This Very Strong Session?

March 14, 2018 - By Henry Gaston

Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.02, from 1.3 in 2017Q2. It increased, as 9 investors sold Cerus Corporation shares while 22 reduced holdings. 11 funds opened positions while 30 raised stakes. 57.26 million shares or 0.28% less from 57.42 million shares in 2017Q2 were reported.
Alliancebernstein L P reported 125,800 shares or 0% of all its holdings. Parametric Associate Ltd Llc accumulated 67,756 shares. Group Inc One Trading Limited Partnership accumulated 0% or 77,583 shares. Envestnet Asset owns 5,377 shares for 0% of their portfolio. Garde holds 13,385 shares. Moreover, Amalgamated Fincl Bank has 0% invested in Cerus Corporation (NASDAQ:CERS). Price T Rowe Assoc Md has invested 0% in Cerus Corporation (NASDAQ:CERS). Ardsley Advisory Partners accumulated 0.03% or 80,000 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Metropolitan Life Insur New York stated it has 71,011 shares. Massachusetts-based Athena Llc has invested 0.02% in Cerus Corporation (NASDAQ:CERS). Voya Investment Mgmt holds 58,633 shares. Swiss Bancorp holds 158,900 shares. Grp reported 69,164 shares. Dekabank Deutsche Girozentrale accumulated 48,000 shares.

The stock of Cerus Corporation (NASDAQ:CERS) is a huge mover today! The stock increased 5.65% or $0.29 during the last trading session, reaching $5.42. About 1.43 million shares traded or 0.87% up from the average. Cerus Corporation (NASDAQ:CERS) has declined 40.83% since March 14, 2017 and is downtrending. It has underperformed by 57.53% the S&P500.
The move comes after 9 months positive chart setup for the $702.42M company. It was reported on Mar, 14 by We have $5.64 PT which if reached, will make NASDAQ:CERS worth $28.10 million more.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on May, 2. They expect $-0.12 EPS, up 33.33 % or $0.06 from last year’s $-0.18 per share. After $-0.10 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 5 analysts covering Cerus (NASDAQ:CERS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cerus had 11 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Thursday, October 5 with “Buy”. Zacks downgraded the shares of CERS in report on Tuesday, August 11 to “Buy” rating. BTIG Research maintained the stock with “Buy” rating in Wednesday, August 19 report. The rating was downgraded by Wedbush on Thursday, December 17 to “Neutral”. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, January 8. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, June 7 report. The firm has “Buy” rating given on Monday, October 30 by Robert W. Baird. As per Wednesday, January 24, the company rating was maintained by Robert W. Baird. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Thursday, November 30 by Robert W. Baird. On Thursday, March 8 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

More recent Cerus Corporation (NASDAQ:CERS) news were published by: which released: “Cerus Corporation: Becoming De-Risked With Plenty Of Upside” on February 27, 2018. Also published the news titled: “Cerus Corporation Reports Record Fourth Quarter and Year End 2017 Results” on March 08, 2018.‘s news article titled: “Form 4 CERUS CORP For: Mar 10 Filed by: Menard Chrystal” with publication date: March 14, 2018 was also an interesting one.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $702.42 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: